Mark your calendar for these important dates related to DDW 2025 abstract submission: 

• Abstract submitter opened: Thursday, Oct. 24, 2024, at 09:00 Eastern time (UTC –4) 

• Abstract submitter closed: Thursday, Dec. 5, 2024, at 21:00 Eastern time (UTC –5)  

• • No edits to abstracts or author strings will be accepted after this deadline. 
• NEW for DDW 2025: Presenting author financial disclosures due: Thursday, Dec. 5, 2024, at 21:00 Eastern time (UTC –5). See full details below.
• Abstract notifications sent to presenting authors: Tuesday, Feb. 11, 2025 

Late-Breaking Abstracts 

• Late-Breaking Abstract submitter opened: Wednesday, Feb. 26, 2025, at 09:00 Eastern time (UTC –5) 
• Late-Breaking Abstract submitter closed: Wednesday, March 5, 2025, at 17:00 Eastern time (UTC –5) 
• Notifications sent to presenting authors: Thursday, April 3, 2025

• Submitting authors must create an account and submit abstracts online. No faxed or mailed abstracts will be accepted. 
• There is a $70 (USD) non-refundable processing charge per abstract ($200 USD for late-breaking abstracts). Please note that this is a  processing fee, not a publishing fee, and that abstracts not selected for presentation at DDW are also subject to the fee.  
• Abstract submission fees are non-refundable. Refunds will not be offered to authors who submit duplicate abstracts, return their abstracts to draft status, or withdraw their abstracts. No refunds will be offered for abstracts not selected for presentation at DDW 2025 or to authors of accepted abstracts not able to attend DDW 2025. 
• Abstracts are not considered submitted until payment information has been received. Authors have the option of paying by Visa®, MasterCard® or American Express®. No invoices, purchase orders or checks will be accepted.
• Authors may edit submitted abstracts until the submission deadline on Dec. 5, 2024. 
• To expedite the submission process, please ensure that your browser allows pop-ups and redirects for the abstract site before you submit. If pop-ups are blocked, the payment page may not display properly. Should you have any issues navigating the payment screen, use the tab key to advance fields. 

New this year:

• Presenting authors are required to submit their financial disclosure by the appropriate abstract submission deadline:
  • Thursday, Dec. 5, 2024, at 21:00 Eastern time (UTC –5), for general submissions; or
  • Wednesday, March 5, 2025 at 17:00 Eastern time (UTC –5) for late-breaking abstract submissions.
• Abstract co-authors are welcome to submit financial disclosure but are NOT required to do so.
• IMPORTANT: Abstracts missing presenting author disclosures as of the submission deadline are in jeopardy of being involuntary withdrawn from consideration for presentation at DDW 2025.

Upon submission of an abstract, the submitting author and presenting author will receive an email message informing them of the abstract submission. The message will contain a link that presenting authors may use to log into the abstract submission site to complete the disclosure form.

Presenting authors must disclose all financial relationships with ineligible companies over the previous 24 months. Authors with such relationships will be asked to list the names of the companies with which they are involved, the benefits received (e.g., salary, consulting fee, ownership interest, etc.) and any roles they play within the named commercial entities (e.g., advisory committee member, board member, employee, shareholder, etc.). Authors without relationships may state that they have no information to disclose.

It is the submitting author’s responsibility to:

• Ensure that the presenting author submits their financial disclosure for DDW 2025 by the Dec. 5 abstract submission deadline.
• Inform any other co-authors that they have been listed on an abstract submission. Only submitters and presenting authors will receive submission confirmation email messages from the submission site after an abstract has been submitted.

Submitting authors are not permitted to:

• Submit disclosure on a co-author’s behalf.
• Add consortia, lab, or other group names to abstract author strings.
  • Only individual author names may be included with abstract submissions. 
  • If entered, group names may be involuntarily removed from abstracts. 

For the 2025 meeting, DDW will offer in-person and online presentation options: 

In-Person Options 

• Oral and Poster Submissions 
  • Abstracts submitted for oral or poster presentation will be considered for presentation on-site at DDW 2025 in San Diego, CA. 
  • If an abstract is selected for lecture or poster presentation, the presenting author is required to register for and attend DDW 2025 in person and present their abstract at the San Diego Convention Center at the date and time specified in their acceptance notification.  
  • Live-streamed or pre-recorded video presentations will not be permitted. 
• ASGE and SSAT Video Abstract Submissions 
  • Video abstracts submitted to ASGE or SSAT by the Dec. 5 deadline will also be considered for presentation on-site at DDW 2025.  
  • If a video abstract is selected by ASGE or SSAT, the presenting author must register for and attend DDW 2025 in person to provide live narration to the video at the date and time specified in the abstract acceptance notification.  
  • Live-streamed or pre-recorded video presentations will not be permitted. 

Online Presentation Option  

• ePoster Submissions 
  • Authors unable to attend DDW in person in San Diego should select the “ePoster only” presentation option when submitting their abstract.
  • ePoster-only abstract submissions will be considered for electronic presentation at the DDW ePosters site during DDW 2025.  
  • Presenters of abstracts accepted for ePoster presentation will be required to register for DDW 2025 and upload an ePoster file to the DDW 2025 ePosters site.  
  • View the DDW 2024 ePosters site to review examples from last year’s meeting.

Author Eligibility 
Authors do not have to be a member of one of the four sponsoring societies to submit an abstract. Submissions from international or trainee authors are welcome. 

Abstract Eligibility 

• Abstracts containing basic, clinical or translational research findings in the fields of gastroenterology, hepatology, endoscopy or gastrointestinal surgery may be submitted. 
• Abstracts that have been submitted to or presented at other national or international meetings may be submitted provided that prior presentation and/or submission to other meetings is declared during the DDW submission process. 
• Abstracts will not be considered for presentation if they have been published as an article or have been accepted for publication (including manuscripts) in printed or electronic formats upon the Dec. 5 submission deadline.  
• Abstracts presented at previous DDW meetings are not eligible for submission. 
• Abstracts that have been submitted to DDW in previous years, but not accepted for presentation, may be resubmitted. 

Contact DDW Administration to verify that your abstract is eligible for submission to DDW 2024. 

When submitting an abstract, authors must select the society to which they wish to submit as well as a submission category and subcategory. Abstracts may not be duplicated in any way or submitted to more than one society or submission category. 

View the full list of abstract submission categories.

For questions about specific submission categories, contact the appropriate sponsoring society: 

• American Association for the Study of Liver Diseases (AASLD)
• American Gastroenterological Association (AGA) 
  • To find the appropriate AGA category and subcategory, please consult the descriptor definitions.
• American Society for Gastrointestinal Endoscopy (ASGE) 
• The Society for Surgery of the Alimentary Tract (SSAT)  

• Abstract titles may not be longer than 255 characters, including spaces. Identifying information like author or institution names must not be included in the title. Abstract titles must be fully capitalized, but authors can format to add superscript or subscript during submission. 
• There is limit of 2,900 characters, including spaces, for the abstract text. Information included in tables or images does not count toward this limit.
• Authors are welcome to but not required to use section headings in their abstracts. If authors elect to using  headings, they will count toward the character limit. 
• Abstracts may include up to two images per abstract. 
  • Images will only be accepted in gif, png, tiff, tif, jpg, or jpeg formats. PDFs will not be accepted. 
  • Any author wishing to include a table with their abstract must submit the table as an image file type. For assistance with saving a Word, Excel or PowerPoint table as an image file, view these instructions on taking a screen shot using Windows or using a Mac. 
  • Images will be published as submitted if accepted for presentation. Authors should remove large borders from images. Large images may be scaled for publication. 
  • Authors are responsible for obtaining any necessary image permissions for inclusion in their abstracts.  
• Abbreviations should conform to the recommendations made by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology. Use the abbreviation in parentheses after the full word the first time it appears. Use no more than three nonstandard abbreviations. 
• Drug products mentioned in abstracts should be identified by their nonproprietary (i.e., generic) names only. Do not capitalize nonproprietary names.

Video abstracts may be submitted to either ASGE or SSAT for consideration for presentation during society forums. Video files must be in either MOV, MPG, MPG4 or MP4 formats and may not exceed one GB in size. All DDW rules and author requirements apply for video submissions. 

Please review the “Additional ASGE Rules” and “Additional SSAT Rules” sections below for more further details on formatting and submitting a video abstract. 

If you have any technical difficulties during your file upload, contact DDW Administration. 

By submitting an abstract, the contact author certifies that they and all co-authors listed on the abstract have read and agree to the following DDW 2025 Rules for Submission.  Violations of any DDW policies may result in a five-year sanction from submitting abstracts to DDW for the submitting author. 

Commitment to Present 

• Submission of an abstract constitutes a commitment by the author(s) to register for DDW and present the abstract (if selected for presentation) at the date, time and location specified in the acceptance notification, if accepted. 
  • Presenting authors of abstracts selected for oral, poster, or ASGE or SSAT video presentation must attend DDW 2025 in person to present their abstract on-site at the San Diego Convention Center. Live-streamed or pre-recorded video presentations will not be permitted. 
  • Presenting authors of abstracts selected for ePoster presentation are required to submit an ePoster file for presentation at the DDW ePosters site. 
• Failure to present may jeopardize acceptance of future abstracts. 
• Abstracts may be presented only by authors listed in the author string at the time of submission. 
• All presentations at DDW 2025 will be in English. Oral abstract presentations must be made by an author who speaks and understands English. 
• Presenters are required to register for the meeting. Registration opens on  Wednesday, Jan. 15, 2025, for DDW sponsoring society members and  Wednesday, Jan. 22, 2025, for nonmembers. 
• Expenses associated with the submission and presentation of an abstract are the sole responsibility of the presenting author. 
• View DDW media and embargo policies. 
  • All abstract data presented at DDW, including poster presentations, is embargoed until 12:01 a.m. PDT on the day of the presentation.
  • Accepted abstracts are made available online to attendees in advance of DDW for itinerary planning purposes. The embargo policy applies to all abstract data regardless of the date of publication in DDW resources. 

Previous Presentation, Publication and Duplication 

• As the world’s largest gathering of physicians and researchers in the GI field, DDW encourages the submission of abstracts that have not yet been presented at other large medical meetings. Abstracts that have been submitted to or presented at other national or international meetings may be submitted provided that prior presentation and/or submission to other meetings is declared during the DDW submission process. 
• Abstracts presented at previous DDW meetings are not eligible for submission. 
• Abstracts will not be considered for presentation if they have been published as an article or have been accepted for publication (including manuscripts) in printed or electronic formats upon the Dec. 5 submission deadline. 
• Abstracts will not be considered for presentation if they have been duplicated in any way. Abstracts may not be submitted to more than one category, subcategory or society for DDW. 
• Abstracts that have been submitted to DDW in previous years but not accepted for presentation are eligible for submission. 
• DDW reserves the right to impose a five-year sanction on any author who submits an abstract that has been duplicated in any way or submits an abstract to more than one category, subcategory or society. 

Corresponding Authors 
The corresponding author certifies that all authors named in their abstract have agreed to its submission for presentation at DDW 2025; that any animal studies conform with the October 2014 revision of The Guiding Principles in the Care and Use of Vertebrate Animals in Research and Training by the American Physiological Society; and that any human experimentation conducted conforms with the principles of the Declaration of Helsinki of the World Medical Association, and meets all the requirements governing informed consent of the country in which the research was performed. 

Co-Author Participation 
By submitting an abstract, the corresponding author affirms that their co-authors have participated sufficiently in the intellectual content, the analysis of data and the writing of the abstract to take public responsibility for it. 

Ethical Statement 
Corresponding authors affirm that they and the other authors submitting an abstract to DDW certify that the data included in their abstract submission and/or presented at DDW is truthful, original, unduplicated and without fraud or fabrication. 

Abstract Copyright Transfer Agreement and Release for Recording 
By submitting an abstract, the corresponding author hereby assigns, conveys, and otherwise transfers all rights, title, interest, and copyright ownership in said work to the four sponsoring societies of DDW effective upon acceptance of said work for publication. “Work” includes the material submitted for publication and any other related material submitted to DDW. The assignment of rights to the four sponsoring societies of DDW includes but is not expressly limited to rights to edit, publish, reproduce, distribute copies, prepare derivative works, include in indices or search databases in print, electronic, or other media, whether or not in use at the time of execution of this agreement, and claim copyright in said work throughout the world for the full duration of the copyright and any renewals or extensions thereof. 

The corresponding author also certifies upon abstract submission that all authors named in the abstract have read and agree to the terms the above copyright and recording policies.  

U.S. Government Employee Authors 
The corresponding author warrants that the work was authored by employees of the U.S. government as part of their official duties and therefore may be published and reproduced without restriction. 

Disclosure Compliance 

• Presenting authors are required to complete the disclosure process at the abstract submission site either disclosing relevant financial relationships with ineligible companies or indicating that none exist. The deadline for presenters to complete their disclosure is  Thursday, Dec. 5, 2024, at 21:00 Eastern time (UTC –5). 
• Abstracts missing presenting author financial disclosures at the submission deadline will be in jeopardy of not being reviewed and involuntarily withdrawn from consideration for DDW 2025. 
• It is the submitting author’s responsibility to ensure that presenting authors submit their financial disclosure for DDW 2025. 
• Submitting authors are not permitted to submit a disclosure on a co-author’s behalf.
• Co-authors are welcome to submit their financial disclosures but are not required to do so.
• Submitters should not include group or consortia names in author strings. If entered, group names may be involuntarily removed from abstracts.

AGA Institute Oral and Poster Abstract Submission 

• AGA welcomes abstract submissions from all career levels for consideration of oral or poster presentation. 
• To find the appropriate category and subcategory, please consult the descriptor definitions.
• Abstracts submitted to the incorrect category or subcategory may be reassigned. 
• Case report submissions are not permitted to be submitted for consideration for presentation at DDW 2025. However, case series submissions will be permitted for consideration for presentation. If you are submitting a case series, please select the category and subcategory in which it best fits.

AGA GI Fellow-Directed Quality-Improvement (QI) Projects Abstract Submission 

• AGA will accept abstract submissions at a special fellow-directed session focusing on quality improvement. 
• Only those currently enrolled in a GI fellowship program may submit abstracts to this descriptor category. 
• The GI fellow MUST be the primary author on the abstract submission. 
• Medical residents are not eligible to submit abstracts to this category. 
• Abstracts submitted and accepted under this category are only eligible for presentation at the special quality improvement session. 
• Please select “GI Fellow-Directed QI Session” for your category and subcategory only if you are submitting for this session. 

ASGE Case Report Submissions
This category permits fellows and trainees to submit cases involving five or fewer patients that have pertinent training points or that amplify clinical experiences. Examples could include a series of interesting or challenging cases or a report illustrating an unusual case or variation on a disease that may differ from the traditional textbook information. 

All ASGE case report submissions are subject to the following policies. Violations of these policies could result in a five-year sanction for submitting abstracts to DDW for the submitting author. 

All case report submissions: 

• Are eligible for oral, poster or ePoster presentation. 
• Must be oriented towards GI training. 
• Only those currently enrolled in a medical school, residency or fellowship training program may submit abstracts to this category. Co-authors do not need to be students or trainees. 
• The student, resident, fellow or trainee MUST be listed as the primary AND presenting author on the abstract submission. 
• Case report submitters are encouraged (but not required) to submit a video along with their written abstract.
  • Videos should illustrate endoscopic findings or techniques that enhance the case report. 
  • Videos must be one minute or less in length. Case report submissions containing videos longer than one minute will be automatically rejected. 
  • Videos will only be presented if accepted to an oral session. 
  • Narration is not necessary but if included, must be in English. 
  • Videos must be formatted in one of the following types: MP4 (.mpg) or QuickTime (.mov). Other video file formats will not be accepted, including .wmv files. 
  • It is recommended that all submissions be submitted in high definition with a recommended video size of 1920×1080 (square pixel ratio) or 1280×720 (square pixel ratio), both for 16:9 aspect ratio. Bit Rate: 5Mbps (for 720) or 10 Mbps (for 1080) 
  • Video size recommended for standard definition: 720×480 (0.9 pixel ratio) for a 4:3 aspect ratio or 720×480 (1.2 pixel ratio) for 16:9 aspect ratio. 
  • Please be sure to use a video frame rate of 30 frames per second. 
  • To ensure good image quality, a video data rate between 3-10 Mbit/second is recommended. 
  • Case report videos CANNOT contain any copyrighted images, videos, photos, etc. (including those obtained from the internet such as a manufacturer’s website) without supporting documentation from the originating source of the copyrighted work. Videos that contain copyrighted images without this documentation will be AUTOMATICALLY REJECTED. 
• Any potential conflict of interest must be disclosed by by presenting authors. A potential conflict of interest exists when a presenting author or the presenting author’s institution has financial or personal relationships that could influence or could be perceived to influence the case presentation. If there are no conflicts of interest, presenting authors must state that there are none. Presenting authors must use the DDW abstract submission disclosure form, which is completed through the submission process. 
• Commercial support for the video production may be acknowledged with a single credit line acknowledging the company/organization providing the support. 
• Case reports CANNOT contain product specific endorsements/group messages or advertising. Do not put product brand names or drug brand names in the video. Generic product and drug names should be used. Efforts must be taken to “black out” any product names that appear within the video. For all narration, when referring to a specific product, you must use the generic term; not doing so could result in an AUTOMATIC REJECTION. 
• Case report images or videos CANNOT contain institutional names or logos. Case reports that contain institutional names and logos will be AUTOMATICALLY REJECTED. 
• Case report submissions and videos CANNOT contain any patient information, physician names, medical record numbers, etc. Videos must be HIPAA (Health Insurance Portability and Accountability Act of 1996) compliant. If there are any perceived HIPAA violations, the submission will be AUTOMATICALLY REJECTED. Please check the endoscopy video and fluoroscopy video portions as well as these have been commonly missed in the past. 
• Copyright must be assigned to the ASGE by ALL authors. 

ASGE Video Submissions
ASGE video forums are designed to showcase interesting endoscopic cases or techniques in the field of gastrointestinal endoscopy. Video presentations can demonstrate accepted techniques, difficult or interesting cases, complications, or innovations within the field of endoscopy. 

Videos may be submitted for consideration for one of the following sessions: 

Video Plenary: This session represents the most prestigious and highest ranking, cutting-edge, fully edited endoscopic videos presented at DDW. These submitted videos receive the top ratings during peer review. The highest scoring video from the peer-reviewed process for each category will be presented a Best-of-the-Best Award in that category. (There is no guarantee that each category will have an award given.) In addition, one final overall winner (the VideoGIE Mel Schapiro Award) will be selected from those identified as Best-of-the-Best videos. This award will be announced at the end of the Video Plenary session. Winners of the Best of the Best awards may be invited to publish the video case in the ASGE’s VideoGIE journal following DDW with applicable author fees waived. 

World Cup of Endoscopy: This session features a friendly international competition of selected videos from various countries. Selection into World Cup will be based on the content of the video, with the objective of selecting one video per country. On average every year, approximately 8 to 10 countries compete in this session. All selected videos will be presented and scored live by an international panel of judges during the session. The top three winners will be declared at the end of the session and receive awards. This session is intended to foster a fun, relaxed, and entertaining atmosphere! The top three winners from the World Cup of Endoscopy session may be invited to publish their videos case in the ASGE journal VideoGIE following DDW with applicable author fees waived. 

Educational Endoscopy: What is your favorite endoscopy technique? These more comprehensive, longer format educational endoscopic videos will be presented at DDW and must be eight minutes or less in duration. The highest scoring video for the best video in this category from the peer-reviewed process will be presented the Distinguished Educational Video (DEV) Award. This award will be announced at the end of the Video Plenary session. The ASGE’s Distinguished Education Video winner may be invited to publish their work in the ASGE journal, VideoGIE following DDW with applicable author fees waived. 

All ASGE video submissions: 

• Require an abstract and will follow the same rules and guidelines as abstracts submitted for oral and poster presentation. 
• Are subjected to a peer-review process and evaluated according to content and audiovisual quality, determining which submission will be accepted and in which category. 
• Are final once submitted. You will NOT be able to make changes to the video or audio of the program. 
• Must include audio narration in English. 
• Must be converted into MP4 or MOV file formats. 
• Video size recommended for high definition: 
  • 1920×1080 (square pixel ratio) or 1280×720 (square pixel ratio), both for 16:9 aspect ratio. 
  • Bit Rate: 5Mbps (for 720) or 10Mbps (for 1080).  
  • Video size recommended for standard definition: 
  • 720×480 (0.9 pixel ratio) for a 4:3 aspect ratio or 720×480 (1.2 pixel ratio) for 16:9 aspect ratio. 

For full rules and instructions on formatting your video, please review the ASGE Video Abstract Submission Criteria and Instructions and the  ASGE PowerPoint Template Guide.

Email ASGE with questions about submitting a video abstract. 

• If an abstract selected for an SSAT Plenary or Quick Shot presentation describes the use of a device, product or drug that is not FDA approved; off-label use of an approved device, product or drug; or unapproved usage of a device, product or drug, the presenting author is required to disclose this information verbally to the learner during his or her presentation. 
• Authors of abstracts selected for SSAT presentations are encouraged to submit a manuscript for potential publication in the  Journal of Gastrointestinal Surgery. 

SSAT Video Submissions 

• A text abstract submission is required. Text should include the key ideas from the video. There is a limit of 255 characters for the title of your abstract submission. There is a limit of 700 characters, including spaces, for the text of your abstract submission (abstract body). Do not include institution or author names in the title, abstract body or file name. 
• Attribution for commercial support must be in the form of a video credit in the beginning of the program. No endorsement or promotion of a specific device or product is allowed. Non-FDA approved use of devices should also be indicated in the opening credits of the video. 
• Duration of the video should be five minutes. Videos longer than five minutes will not be considered. Although sound is encouraged with video submission so that its content may be properly evaluated, if selected for presentation, no audio playback capabilities will be provided. The presenting author will need to supply live narration to the video.  
• Permission for all copyrighted material (drawings, illustrations, video footage) must be obtained with attribution of permissions included in the closing credits. 
• Surgical videos submitted online should not include author and institution information. Any patient identifying information must be excluded or obscured from video films and narration. 
• If accepted, changes cannot be made to the submitted video file as videos will be uploaded on your behalf prior to the start of the meeting for conversion/playback purposes. If a PowerPoint presentation is required for introduction, you must indicate this in the submission. 

Authors may make edits to submitted abstracts any time prior to the Dec. 5 submission deadline. To make edits, submitting authors should log in at the submission site, click the “submission” tab and use the dropdown menu next to the abstract title to select “return to draft.” The abstract will then be available for editing. Once all changes have been made, submitting authors must save and resubmit the abstract.

Please note that authors must resubmit an abstract that has been edited after the initial submission. Any abstracts in draft status at the submission deadline will not be reviewed or considered for presentation at DDW. There is no fee to resubmit an abstract. 

No edits or additions to abstracts, author strings, or author institutions will be accepted after the Dec. 5 submission deadline.

• Abstract acceptance notifications will be sent by email to presenting authors on  Tuesday, Feb. 11, 2025. It is the responsibility of the presenting author to notify any co-authors of the decision. 
• Presenting authors must formally accept their invitations to present at the submission site by 17:00 Eastern time (UTC –5) on Wednesday, Feb. 19, 2025. If an invitation remains unanswered after this date, the abstract may be withdrawn. 
• Declined invitations will result in automatic withdrawal. 
• No refunds will be provided for declined or withdrawn abstracts. 

To give authors the opportunity to submit novel research that was not complete at the general submission deadline, DDW will accept clinical and basic science late-breaking abstract submissions from  09:00 Eastern time (UTC –5) on Feb. 26, 2025, through  17:00 Eastern time (UTC –5) on Wednesday, March 5, 2025. 

LBA submissions may be selected for oral presentation and should feature newsworthy, high-impact data that was not available at the Dec. 5 general submission deadline. Abstracts will be scored on the quality and significance of the submitted evidence. DDW welcomes submissions describing new therapies and unapproved medications, large phase II or III clinical trial results, and novel basic science discoveries that have not been published or presented at other meetings. 

The LBA submission period is not an extension to the general submission period. Case reports, case series, literature reviews, retrospective studies, and abstracts featuring results or data available on the Dec. 5 general submission deadline are ineligible as late-breaking abstracts and will not be considered. Revisions to previously submitted abstracts and abstracts that have been or will be published (including manuscripts) or presented in any other scientific venue prior to DDW 2025 are also ineligible and will not be reviewed. All formatting and submission rules apply to late-breaking submissions. 

Acceptance notifications will be sent to presenting authors on Thursday, April 3, 2025. 

By submitting a late-breaking abstract, all authors acknowledge and agree to the following policies: 

• Submission of a late-breaking abstract constitutes an obligation for the presenting author to attend the Late-Breaking Plenary session in person at DDW 2025 if the abstract is accepted. No video or pre-recorded late-breaking abstract presentations will be permitted.
• Late-breaking abstract submissions will considered only for lecture presentation at DDW 2025. Late-breaking submissions not be considered for poster or ePoster presentation.
• All formatting and submission rules listed in the DDW 2025 Abstract Submission Guidelines apply to late-breaking submissions, with the following exception: Any abstract that has been or will be published (including manuscripts) or presented in any other venue prior to DDW 2025 is ineligible for submission as a late-breaking abstract.
• As part of the submission process, the submitting author will be required to briefly explain why their abstract should be considered late-breaking and why it was not possible to have submitted the abstract by the Dec. 5 general deadline.
• There is a $200 fee to submit a late-breaking abstract. Refunds will not be offered to authors whose abstracts are not selected for presentation or that do not meet the DDW late-breaking abstract criteria.
• After April 3, 2025, late-breaking submissions cannot be withdrawn. Abstracts accepted for presentation will not be able to be excluded from the DDW publications.

DDW will withdraw an abstract upon written request from the submitting author. Requests for withdrawal must be made by  Friday, Feb. 28, 2025. After this date, DDW cannot guarantee that a withdrawn abstract will be excluded from publication. 

Requests to withdraw an abstract must be made by the submitting or presenting author and must contain the submitting author’s name, abstract title, and control ID number. Withdrawal requests will be accepted beginning on Monday, Dec. 16, 2024. Submission fee refunds will not be provided for withdrawn abstracts.  

Abstracts selected for presentation at DDW 2025 by AASLD, AGA and SSAT will be published online in the May 2025 Gastroenterology  supplement. Abstracts selected for presentation at DDW 2025 by ASGE will be published online in the GIE: Gastrointestinal Endoscopy  supplement. 

DDW will award up to 20 Basic Science Travel Awards to early career researchers for the 2025 meeting. Selected authors of basic science abstracts will receive a $1,000 (USD) grant.

DDW’s sponsoring societies also offer several grants for abstract authors. Learn more.

Contact DDW Administration with any questions pertaining to DDW abstract submission.